Fig. 5

(Lipo + M)@E NPs regulated the phenotypic transformation of VSMCs by reducing PCSK9 levels. (A) Represented photograph showing the protein expressions of PCSK9, OPN, Vimentin, and α-SMA in VSMCs after treatment with Evol, Lipo@E NPs, and (Lipo + M)@E NPs. (B) The relative quantification analysis of PCSK9, OPN, Vimentin, and α-SMA. Immunofluorescence images and quantitative analysis of PCSK9 (red) (C&D), OPN (yellow) (E&F), Vimentin (red) (G&H), and α-SMA (green) (I&J) in VSMCs after treatment with (Lipo + M)@E NPs. Scale bars = 20 μm. 1: Control, 2: Model, 3: Evol, 4: Lipo@E NPs, 5: Lipo + M)@E NPs. Data are means ± SD, n = 3, ^##P < 0.01, ^###P < 0.001 vs. the Control. ^**P < 0.01, ^***P < 0.001 vs. the Model